Interleukin-1 beta (IL-1β) contributes to hepatic injury and fibrosis [34] and AT1 blockade has been shown to decrease hepatic fibrosis in patients with NAFLD [35]. The gene discussed is IL1B; the disease is metabolic dysfunction-associated steatotic liver disease.